Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2011, Article ID 708404, 13 pages
http://dx.doi.org/10.4061/2011/708404
Review Article

Neuropathology and Neurochemistry of Nonmotor Symptoms in Parkinson's Disease

Institut de Neuropatologia, Servei Anatomia Patològica, IDIBELL-Hospital Universitari de Bellvitge, Universitat de Barcelona, carrer Feixa LLarga sn, CIBERNED, 08907 Hospitalet de LLobregat, Spain

Received 11 October 2010; Accepted 16 December 2010

Academic Editor: Irena Rektorova

Copyright © 2011 Isidro Ferrer. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. S. Forno, “Neuropathology of Parkinson's disease,” Journal of Neuropathology and Experimental Neurology, vol. 55, no. 3, pp. 259–272, 1996. View at Google Scholar · View at Scopus
  2. K. Jellinger and Y. Mizuno, “Parkinson's disease,” in Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders, D. Dickson, Ed., pp. 159–187, ISN Neuropathol Press, Basel, Switzerland, 2003. View at Google Scholar
  3. H. Braak, D. Sandmann-Keil, W. Gai, and E. Braak, “Extensive axonal Lewy neurites in Parkinson's disease: a novel pathological feature revealed by α-synuclein immunocytochemistry,” Neuroscience Letters, vol. 265, no. 1, pp. 67–69, 1999. View at Publisher · View at Google Scholar · View at Scopus
  4. D. W. Dickson, “α-Synuclein and the Lewy body disorders,” Current Opinion in Neurology, vol. 14, no. 4, pp. 423–432, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Goedert, “Parkinson's disease and other α-synucleinopathies,” Clinical Chemistry and Laboratory Medicine, vol. 39, no. 4, pp. 308–312, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. H. Braak and K. Del Tredici, “Cortico-basal ganglia-cortical circuitry in Parkinson's disease reconsidered,” Experimental Neurology, vol. 212, no. 1, pp. 226–229, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. D. W. Dickson, H. Braak, J. E. Duda et al., “Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria,” The Lancet Neurology, vol. 8, no. 12, pp. 1150–1157, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. P. G. Ince and I. G. McKeith, “Dementia with Lewy bodies,” in Neurodegeneration, D. Dickson, Ed., pp. 188–199, ISN Neuropath Press, Basel, Switzerland, 2003. View at Google Scholar
  9. I. McKeith, “Clinical aspects of dementia with Lewy bodies,” in Handbook of Clinical Neurology, D. C. Duyckaerts and I. Litvan, Eds., vol. 89, pp. 306–311, Elsevier, New York, NY, USA, 3rd edition, 2008. View at Google Scholar
  10. J. Lowe, “Neuropathology of dementia with Lewy bodies,” in Handbook of Clinical Neurology, D. C. Duyckaerts and I. Litvan, Eds., vol. 89, pp. 321–330, Elsevier, New York, NY, USA, 3rd edition, 2008. View at Google Scholar
  11. C. W. Shults, “Lewy bodies,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 6, pp. 1661–1668, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Wakabayashi, K. Tanji, F. Mori, and H. Takahashi, “The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of α-synuclein aggregates,” Neuropathology, vol. 27, no. 5, pp. 494–506, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. J. B. Leverenz, I. Umar, Q. Wang et al., “Proteomic identification of novel proteins in cortical Lewy bodies,” Brain Pathology, vol. 17, no. 2, pp. 139–145, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. Q. Xia, L. Liao, D. Cheng et al., “Proteomic identification of novel proteins associated with Lewy bodies,” Frontiers in Bioscience, vol. 13, no. 10, pp. 3850–3856, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. M. G. Spillantini, M. L. Schmidt, V. M. Y. Lee, J. Q. Trojanowski, R. Jakes, and M. Goedert, “α-synuclein in Lewy bodies,” Nature, vol. 388, no. 6645, pp. 839–840, 1997. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Wakabayashi, K. Matsumoto, K. Takayama, M. Yoshimoto, and H. Takahashi, “NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease,” Neuroscience Letters, vol. 249, pp. 180–182, 1997. View at Google Scholar
  17. M. Baba, S. Nakajo, P. H. Tu et al., “Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies,” American Journal of Pathology, vol. 152, no. 4, pp. 879–884, 1998. View at Google Scholar · View at Scopus
  18. M. Hashimoto and E. Masliah, “Alpha-synuclein in Lewy body disease and Alzheimer's disease,” Brain Pathology, vol. 9, no. 4, pp. 707–720, 1999. View at Google Scholar · View at Scopus
  19. J. E. Duda, B. I. Giasson, Q. Chen et al., “Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies,” American Journal of Pathology, vol. 157, no. 5, pp. 1439–1445, 2000. View at Google Scholar · View at Scopus
  20. B. I. Giasson, J. E. Duda, I. V. J. Murray et al., “Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions,” Science, vol. 290, no. 5493, pp. 985–989, 2000. View at Publisher · View at Google Scholar · View at Scopus
  21. H. Fujiwara, M. Hasegawa, N. Dohmae et al., “α-synuclein is phosphorylated in synucleinopathy lesions,” Nature Cell Biology, vol. 4, no. 2, pp. 160–164, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Iwatsubo, “Aggregation of α-synuclein in the pathogenesis of Parkinson's disease,” Journal of Neurology, Supplement, vol. 250, supplement 3, pp. 11–14, 2003. View at Google Scholar · View at Scopus
  23. J. P. Anderson, D. E. Walker, J. M. Goldstein et al., “Phosphorylation of Ser-129 is the dominant pathological modification of α-synuclein in familial and sporadic Lewy body disease,” Journal of Biological Chemistry, vol. 281, no. 40, pp. 29739–29752, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. M. H. Polymeropoulos, C. Lavedan, E. Leroy et al., “Mutation in the α-synuclein gene identified in families with Parkinson's disease,” Science, vol. 276, no. 5321, pp. 2045–2047, 1997. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Krüger, W. Kuhn, T. Müller et al., “Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease,” Nature Genetics, vol. 18, no. 2, pp. 106–108, 1998. View at Google Scholar · View at Scopus
  26. J. J. Zarranz, J. Alegre, J. C. Gómez-Esteban et al., “The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia,” Annals of Neurology, vol. 55, no. 2, pp. 164–173, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. A. B. Singleton, M. Farrer, J. Johnson et al., “α-synuclein locus triplication causes Parkinson's disease,” Science, vol. 302, no. 5646, p. 841, 2003. View at Publisher · View at Google Scholar
  28. M. C. Chartier-Harlin, J. Kachergus, C. Roumier et al., “α-synuclein locus duplication as a cause of familial Parkinson's disease,” The Lancet, vol. 364, no. 9440, pp. 1167–1169, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. P. Ibáñez, A. M. Bonnet, B. Débarges et al., “Causal relation between α-synuclein gene duplication and familial Parkinson's disease,” The Lancet, vol. 364, no. 9440, pp. 1169–1171, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. K. Nishioka, S. Hayashi, M. J. Farrer et al., “Clinical heterogeneity of α-synuclein gene duplication in Parkinson's disease,” Annals of Neurology, vol. 59, no. 2, pp. 298–309, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Jowaed, I. Schmitt, O. Kaut, and U. Wüllner, “Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains,” Journal of Neuroscience, vol. 30, no. 18, pp. 6355–6359, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. E. Doxakis, “Post-transcriptional regulation of α-synuclein expression by mir-7 and mir-153,” Journal of Biological Chemistry, vol. 285, no. 17, pp. 12726–12734, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. E. Junn, K. W. Lee, S. J. Byeong, T. W. Chan, J. Y. Im, and M. M. Mouradian, “Repression of α-synuclein expression and toxicity by microRNA-7,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 31, pp. 13052–13057, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. G. Wang, J. M. van der Walt, G. Mayhew et al., “Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of α-synuclein,” American Journal of Human Genetics, vol. 82, no. 2, pp. 283–289, 2008. View at Publisher · View at Google Scholar
  35. T. Kitada, S. Asakawa, N. Hattori et al., “Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism,” Nature, vol. 392, no. 6676, pp. 605–608, 1998. View at Publisher · View at Google Scholar · View at Scopus
  36. V. Bonifati, P. Rizzu, M. J. Van Baren et al., “Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism,” Science, vol. 299, no. 5604, pp. 256–259, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. E. M. Valente, P. M. Abou-Sleiman, V. Caputo et al., “Hereditary early-onset Parkinson's disease caused by mutations in PINK1,” Science, vol. 304, no. 5674, pp. 1158–1160, 2004. View at Publisher · View at Google Scholar
  38. A. Zimprich, S. Biskup, P. Leitner et al., “Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology,” Neuron, vol. 44, no. 4, pp. 601–607, 2004. View at Publisher · View at Google Scholar · View at Scopus
  39. C. Paisán-Ruíz, S. Jain, E. W. Evans et al., “Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease,” Neuron, vol. 44, no. 4, pp. 595–600, 2004. View at Publisher · View at Google Scholar
  40. K. M. Strauss, L. M. Martins, H. Plun-Favreau et al., “Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease,” Human Molecular Genetics, vol. 14, no. 15, pp. 2099–2111, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. E. Leroy, R. Boyer, G. Auburger et al., “The ubiquitin pathway in Parkinson's disease,” Nature, vol. 395, no. 6701, pp. 451–452, 1998. View at Publisher · View at Google Scholar · View at Scopus
  42. E. Sidransky, M. A. Nalls, J. O. Aasly et al., “Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease,” New England Journal of Medicine, vol. 361, no. 17, pp. 1651–1661, 2009. View at Publisher · View at Google Scholar
  43. T. Gasser, “Molecular pathogenesis of Parkinson disease: insights from genetic studies,” Expert reviews in molecular medicine, vol. 11, article e22, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. B. Thomas and M. F. Beal, “Parkinson's disease,” Human molecular genetics, vol. 16, pp. R183–194, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. J. Hardy, P. Lewis, T. Revesz, A. Lees, and C. Paisan-Ruiz, “The genetics of Parkinson's syndromes: a critical review,” Current Opinion in Genetics and Development, vol. 19, no. 3, pp. 254–265, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. G. Santpere and I. Ferrer, “LRRK2 and neurodegeneration,” Acta Neuropathologica, vol. 117, no. 3, pp. 227–246, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. L. Samaranch, O. Lorenzo-Betancor, J. M. Arbelo et al., “PINK1-linked parkinsonism is associated with Lewy body pathology,” Brain, vol. 133, no. 4, pp. 1128–1142, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. H. Braak, K. Del Tredici, H. Bratzke, J. Hamm-Clement, D. Sandmann-Keil, and U. Rüb, “Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages),” Journal of Neurology, Supplement, vol. 249, no. 3, pp. III1–III5, 2002. View at Google Scholar · View at Scopus
  49. H. Braak, K. Del Tredici, U. Rüb, R. A. I. De Vos, E. N. H. Jansen Steur, and E. Braak, “Staging of brain pathology related to sporadic Parkinson's disease,” Neurobiology of Aging, vol. 24, no. 2, pp. 197–211, 2003. View at Publisher · View at Google Scholar · View at Scopus
  50. H. Braak, E. Ghebremedhin, U. Rüb, H. Bratzke, and K. Del Tredici, “Stages in the development of Parkinson's disease-related pathology,” Cell and Tissue Research, vol. 318, no. 1, pp. 121–134, 2004. View at Publisher · View at Google Scholar · View at Scopus
  51. R. Frigerio, H. Fujishiro, D. M. Maraganore et al., “Comparison of risk factor profiles in incidental Lewy body disease and Parkinson disease,” Archives of Neurology, vol. 66, no. 9, pp. 1114–1119, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. H. Uchikado, W.-L. Lin, M. W. Delucia, and D. W. Dickson, “Alzheimer disease with amygdala Lewy bodies: a distinct form of α-synucleinopathy,” Journal of Neuropathology and Experimental Neurology, vol. 65, no. 7, pp. 685–697, 2006. View at Publisher · View at Google Scholar
  53. K. Kosaka, “Dementia and neuropathology in Lewy body disease,” Advances in neurology, vol. 60, pp. 456–463, 1993. View at Google Scholar · View at Scopus
  54. J. Zaccai, C. Brayne, I. McKeith, F. Matthews, and P. G. Ince, “MRC cognitive function, ageing neuropathology study, patterns and stages of α-synucleinopathy: relevance in a population-based cohort,” Neurology, vol. 70, pp. 1042–1048, 2008. View at Google Scholar
  55. K. A. Jellinger, “Lewy body-related α-synucleinopathy in the aged human brain,” Journal of Neural Transmission, vol. 111, no. 10-11, pp. 1219–1235, 2004. View at Publisher · View at Google Scholar · View at Scopus
  56. H. Braak, R. A. I. De Vos, J. Bohl, and K. Del Tredici, “Gastric α-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology,” Neuroscience Letters, vol. 396, no. 1, pp. 67–72, 2006. View at Publisher · View at Google Scholar · View at Scopus
  57. K. A. Jellinger, “A critical reappraisal of current staging of Lewy-related pathology in human brain,” Acta Neuropathologica, vol. 116, no. 1, pp. 1–16, 2008. View at Publisher · View at Google Scholar · View at Scopus
  58. K. A. Jellinger, “A critical evaluation of current staging of α-synuclein pathology in Lewy body disorders,” Biochimica et Biophysica Acta, vol. 1792, no. 7, pp. 730–740, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. K. R. Chaudhuri, L. Yates, and P. Martinez-Martin, “The non-motor symptom complex of Parkinson's disease: a comprehensive assessment is essential,” Current Neurology and Neuroscience Reports, vol. 5, no. 4, pp. 275–283, 2005. View at Google Scholar · View at Scopus
  60. R. B. Postuma, A. E. Lang, J. Massicotte-Marquez, and J. Montplaisir, “Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder,” Neurology, vol. 66, no. 6, pp. 845–851, 2006. View at Publisher · View at Google Scholar
  61. A. Iranzo, J. L. Molinuevo, J. Santamaría et al., “Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study,” Lancet Neurology, vol. 5, no. 7, pp. 572–577, 2006. View at Publisher · View at Google Scholar · View at Scopus
  62. A. Siderowf and M. B. Stern, “Preclinical diagnosis of Parkinson's disease: are we there yet?” Current Neurology and Neuroscience Reports, vol. 6, no. 4, pp. 295–301, 2006. View at Publisher · View at Google Scholar · View at Scopus
  63. E. Tolosa, Y. Compta, and C. Gaig, “The premotor phase of Parkinson's disease,” Parkinsonism and Related Disorders, vol. 13, pp. S2–S7, 2007. View at Publisher · View at Google Scholar · View at Scopus
  64. W. Poewe, “Dysautonomia and cognitive dysfunction in Parkinson's disease,” Movement Disorders, vol. 22, supplement 17, pp. S374–S378, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. T. Ziemssen and H. Reichmann, “Non-motor dysfunction in Parkinson's disease,” Parkinsonism and Related Disorders, vol. 13, no. 6, pp. 323–332, 2007. View at Publisher · View at Google Scholar · View at Scopus
  66. B. Herting, S. Schulze, H. Reichmann, A. Haehner, and T. Hummel, “A longitudinal study of olfactory function in patients with idiopathic Parkinson's disease,” Journal of Neurology, vol. 255, no. 3, pp. 367–370, 2008. View at Publisher · View at Google Scholar · View at Scopus
  67. E. C. H. Wolters and H. Braak, “Parkinson's disease: premotor clinico-pathological correlations,” Journal of Neural Transmission, Supplement, no. 70, pp. 309–319, 2006. View at Google Scholar · View at Scopus
  68. W. Poewe, “Non-motor symptoms in Parkinson's disease,” European Journal of Neurology, vol. 15, supplement 1, pp. 14–20, 2008. View at Publisher · View at Google Scholar · View at Scopus
  69. G. W. Ross, H. Petrovitch, R. D. Abbott et al., “Association of olfactory dysfunction with risk for future Parkinson's disease,” Annals of Neurology, vol. 63, no. 2, pp. 167–173, 2008. View at Publisher · View at Google Scholar · View at Scopus
  70. G. Natale, L. Pasquali, S. Ruggieri, A. Paparelli, and F. Fornai, “Parkinson's disease and the gut: a well known clinical association in need of an effective cure and explanation,” Neurogastroenterology and Motility, vol. 20, no. 7, pp. 741–749, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. S. E. Daniel and C. H. Hawkes, “Preliminary diagnosis of Parkinson's disease by olfactory bulb pathology,” The Lancet, vol. 340, no. 8812, p. 186, 1992. View at Google Scholar · View at Scopus
  72. R. K. B. Pearce, C. H. Hawkes, and S. E. Daniel, “The anterior olfactory nucleus in Parkinson's disease,” Movement Disorders, vol. 10, no. 3, pp. 283–287, 1995. View at Publisher · View at Google Scholar · View at Scopus
  73. K. Del Tredici, U. Rüb, R. A. I. De Vos, J. R. E. Bohl, and H. Braak, “Where does Parkinson disease pathology begin in the brain?” Journal of Neuropathology and Experimental Neurology, vol. 61, no. 5, pp. 413–426, 2002. View at Google Scholar · View at Scopus
  74. A. Bloch, A. Probst, H. Bissig, H. Adams, and M. Tolnay, “α-Synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects,” Neuropathology and Applied Neurobiology, vol. 32, no. 3, pp. 284–295, 2006. View at Publisher · View at Google Scholar
  75. P. S. Hubbard, M. M. Esiri, M. Reading, R. McShane, and Z. Nagy, “Alpha-synuclein pathology in the olfactory pathways of dementia patients,” Journal of Anatomy, vol. 211, no. 1, pp. 117–124, 2007. View at Publisher · View at Google Scholar · View at Scopus
  76. H. Fujishiro, R. Frigerio, M. Burnett et al., “Cardiac sympathetic denervation correlates with clinical and pathologic stages of Parkinson's disease,” Movement Disorders, vol. 23, no. 8, pp. 1085–1092, 2008. View at Publisher · View at Google Scholar · View at Scopus
  77. I. Ubeda-Bañon, D. Saiz-Sanchez, C. De La Rosa-Prieto, L. Argandoña-Palacios, S. Garcia-Muñozguren, and A. Martinez-Marcos, “α-Synucleinopathy in the human olfactory system in Parkinson's disease: involvement of calcium-binding protein- and substance P-positive cells,” Acta Neuropathologica, vol. 119, no. 6, pp. 723–735, 2010. View at Publisher · View at Google Scholar · View at Scopus
  78. T. G. Beach, C. L. White 3rd, C. L. Hladik et al., “Arizona Parkinson's Disease Consortium. Olfactory bulb a-synucleinopathy has high specificity and sensitivity for Lewy body disorders,” Acta Neuropathologica, vol. 117, no. 2, pp. 215–216, 2009. View at Publisher · View at Google Scholar
  79. L. Parkkinen, L. Silveira-Moriyama, J. L. Holton, A. J. Lees, and T. Revesz, “Can olfactory bulb biopsy be justified for the diagnosis of Parkinson's disease? Comments on "olfactory bulb α-synucleinopathy has high specificity and sensitivity for Lewy body disorders",” Acta Neuropathologica, vol. 117, no. 2, pp. 213–214, 2009. View at Publisher · View at Google Scholar
  80. E. Biagiotti, P. Ferri, R. Dringen, P. Del Grande, and P. Ninfali, “Glucose-6-phosphate dehydrogenase and NADPH-consuming enzymes in the rat olfactory bulb,” Journal of Neuroscience Research, vol. 80, no. 3, pp. 434–441, 2005. View at Publisher · View at Google Scholar · View at Scopus
  81. R. A. Vaishnav, M. L. Getchell, H. F. Poon et al., “Oxidative stress in the aging murine olfactory bulb: redox proteomics and cellular localization,” Journal of Neuroscience Research, vol. 85, no. 2, pp. 373–385, 2007. View at Publisher · View at Google Scholar · View at Scopus
  82. M. Hosokawa, “A higher oxidative status accelerates senescence and aggravates age-dependent disorders in SAMP strains of mice,” Mechanisms of Ageing and Development, vol. 123, no. 12, pp. 1553–1561, 2002. View at Publisher · View at Google Scholar · View at Scopus
  83. N. I. Bohnen, M. L. T. M. Müller, V. Kotagal et al., “Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson's disease,” Brain, vol. 133, no. 6, pp. 1747–1754, 2010. View at Publisher · View at Google Scholar · View at Scopus
  84. D. G. Healy, M. Falchi, S. S. O'Sullivan et al., “Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study,” The Lancet Neurology, vol. 7, no. 7, pp. 583–590, 2008. View at Publisher · View at Google Scholar · View at Scopus
  85. G. Kägi, C. Klein, N. W. Wood et al., “Nonmotor symptoms in Parkin gene-related parkinsonism,” Movement Disorders, vol. 25, no. 9, pp. 1279–1284, 2010. View at Publisher · View at Google Scholar
  86. K. Wakabayashi, H. Takahashi, E. Ohama, and F. Ikuta, “Parkinson's disease: an immunohistochemical study of Lewy body-containing neurons in the enteric nervous system,” Acta Neuropathologica, vol. 79, no. 6, pp. 581–583, 1990. View at Publisher · View at Google Scholar · View at Scopus
  87. S. Takeda, K. Yamazaki, T. Miyakawa, and H. Arai, “Parkinson's disease with involvement of the parasympathetic ganglia,” Acta Neuropathologica, vol. 86, no. 4, pp. 397–398, 1993. View at Google Scholar · View at Scopus
  88. K. Wakabayashi and H. Takahashi, “Neuropathology of autonomic nervous system in Parkinson's disease,” European Neurology, vol. 38, supplement 2, pp. 2–7, 1997. View at Google Scholar
  89. K. Hague, P. Lento, S. Morgello, S. Caro, and H. Kaufmann, “The distribution of Lewy bodies in pure autonomic failure: autopsy findings and review of the literature,” Acta Neuropathologica, vol. 94, no. 2, pp. 192–196, 1997. View at Publisher · View at Google Scholar · View at Scopus
  90. G. Micieli, P. Tosi, S. Marcheselli, and A. Cavallini, “Autonomic dysfunction in Parkinson's disease,” Neurological Sciences, vol. 24, supplement 1, pp. S32–S34, 2003. View at Publisher · View at Google Scholar
  91. E. E. Benarroch, A. M. Schmeichel, P. A. Low, B. F. Boeve, P. Sandroni, and J. E. Parisi, “Involvement of medullary regions controlling sympathetic output in Lewy body disease,” Brain, vol. 128, no. 2, pp. 338–344, 2005. View at Publisher · View at Google Scholar · View at Scopus
  92. A. Minguez-Castellanos, C. E. Chamorro, F. Escamilla-Sevilla et al., “Do α-synuclein aggregates in autonomic plexuses predate Lewy body disorders?: a cohort study,” Neurology, vol. 68, no. 23, pp. 2012–2018, 2007. View at Publisher · View at Google Scholar · View at Scopus
  93. A. Probst, A. Bloch, and M. Tolnay, “New insights into the pathology of Parkinson's disease: does the peripheral autonomic system become central?” European Journal of Neurology, vol. 15, supplement 1, pp. 1–4, 2008. View at Publisher · View at Google Scholar
  94. M. Oinas, A. Paetau, L. Myllykangas, I. L. Notkola, H. Kalimo, and T. Polvikoski, “α-Synuclein pathology in the spinal cord autonomic nuclei associates with α-synuclein pathology in the brain: a population-based Vantaa 85+ study,” Acta Neuropathologica, vol. 119, no. 6, pp. 715–722, 2010. View at Publisher · View at Google Scholar · View at Scopus
  95. K. Wakabayashi, H. Takahashi, S. Takeda, E. Ohama, and F. Ikuta, “Parkinson's disease: the presence of Lewy bodies in Auerbach's and Meissner's plexuses,” Acta Neuropathologica, vol. 76, no. 3, pp. 217–221, 1988. View at Google Scholar · View at Scopus
  96. T. G. Beach, C. H. Adler, L. I. Sue et al., “Arizona Parkinson’s Disease Consortium. Multi-organ distribution of phosphorylated α-synuclein histopathology in subjects with Lewy body disorders,” Acta Neuropathologica, vol. 119, no. 6, pp. 689–702, 2010. View at Publisher · View at Google Scholar
  97. K. Iwanaga, K. Wakabayashi, M. Yoshimoto et al., “Lewy body-type degeneration in cardiac plexus in Parkinson's and incidental Lewy body diseases,” Neurology, vol. 52, no. 6, pp. 1269–1271, 1999. View at Google Scholar · View at Scopus
  98. H. Takatsu, H. Nishida, H. Matsuo et al., “Cardiac sympathetic denervation from the early stage of Parkinson's disease: clinical and experimental studies with radiolabeled MIBG,” Journal of Nuclear Medicine, vol. 41, no. 1, pp. 71–77, 2000. View at Google Scholar · View at Scopus
  99. J. Mitsui, Y. Saito, T. Momose et al., “Pathology of the sympathetic nervous system corresponding to the decreased cardiac uptake in 123I-metaiodobenzylguanidine (MIBG) scintigraphy in a patient with Parkinson disease,” Journal of the Neurological Sciences, vol. 243, no. 1-2, pp. 101–104, 2006. View at Publisher · View at Google Scholar
  100. K. Kashihara, M. Ohno, S. Kawada, and Y. Okumura, “Reduced cardiac uptake and enhanced washout of123I-MIBG in pure autonomic failure occurs conjointly with Parkinson's disease and dementia with Lewy bodies,” Journal of Nuclear Medicine, vol. 47, no. 7, pp. 1099–1101, 2006. View at Google Scholar
  101. H. Oka, M. Morita, K. Onouchi, M. Yoshioka, S. Mochio, and K. Inoue, “Cardiovascular autonomic dysfunction in dementia with Lewy bodies and Parkinson's disease,” Journal of the Neurological Sciences, vol. 254, no. 1-2, pp. 72–77, 2007. View at Publisher · View at Google Scholar · View at Scopus
  102. H. Sawada, T. Oeda, K. Yamamoto et al., “Diagnostic accuracy of cardiac metaiodobenzylguanidine scintigraphy in Parkinson disease,” European Journal of Neurology, vol. 16, no. 2, pp. 174–182, 2009. View at Publisher · View at Google Scholar · View at Scopus
  103. S. Orimo, T. Amino, Y. Itoh et al., “Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease,” Acta Neuropathologica, vol. 109, no. 6, pp. 583–588, 2005. View at Publisher · View at Google Scholar · View at Scopus
  104. S. Orimo, A. Takahashi, T. Uchihara et al., “Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson's disease,” Brain Pathology, vol. 17, no. 1, pp. 24–30, 2007. View at Publisher · View at Google Scholar · View at Scopus
  105. S. Orimo, T. Uchihara, A. Nakamura et al., “Axonal α-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease,” Brain, vol. 131, no. 3, pp. 642–650, 2008. View at Publisher · View at Google Scholar · View at Scopus
  106. K. Stiasny-Kolster, Y. Doerr, J. C. Möller et al., “Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for α-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT,” Brain, vol. 128, no. 1, pp. 126–137, 2005. View at Publisher · View at Google Scholar
  107. B. Tijero, J. C. Gomez-Esteban, V. Llorens et al., “Cardiac sympathetic denervation precedes nigrostriatal loss in the E46K mutation of the α-synuclein gene (SNCA),” Clinical Autonomic Research, vol. 20, no. 4, pp. 267–269, 2010. View at Publisher · View at Google Scholar
  108. C. G. Goetz, B. Ouyang, A. Negron, and G. T. Stebbins, “Hallucinations and sleep disorders in PD: ten-year prospective longitudinal study,” Neurology, vol. 75, no. 20, pp. 1773–1779, 2010. View at Publisher · View at Google Scholar
  109. R. Manni, M. Terzaghi, A. Repetto, R. Zangaglia, and C. Pacchetti, “Complex paroxysmal nocturnal behaviors in Parkinson's disease,” Movement Disorders, vol. 25, no. 8, pp. 985–990, 2010. View at Publisher · View at Google Scholar · View at Scopus
  110. B. F. Boeve, “REM sleep behavior disorder: updated review of the core features, the REM sleep behavior disorder-neurodegenerative disease association, evolving concepts, controversies, and future directions,” Annals of the New York Academy of Sciences, vol. 1184, pp. 15–54, 2010. View at Publisher · View at Google Scholar · View at Scopus
  111. D. O. Claassen, K. A. Josephs, J. E. Ahlskog, M. H. Silber, M. Tippmann-Peikert, and B. F. Boeve, “REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century,” Neurology, vol. 75, no. 6, pp. 494–499, 2010. View at Publisher · View at Google Scholar
  112. I. Arnulf, M. Ferraye, V. Fraix et al., “Sleep induced by stimulation in the human pedunculopontine nucleus area,” Annals of Neurology, vol. 67, no. 4, pp. 546–549, 2010. View at Publisher · View at Google Scholar · View at Scopus
  113. A. Marques, K. Dujardin, M. Boucart et al., “REM sleep behaviour disorder and visuoperceptive dysfunction: a disorder of the ventral visual stream?” Journal of Neurology, vol. 257, no. 3, pp. 383–391, 2010. View at Publisher · View at Google Scholar · View at Scopus
  114. T. C. Thannickal, Y. Y. Lai, and J. M. Siegel, “Hypocretin (orexin) cell loss in Parkinson's disease,” Brain, vol. 130, no. 6, pp. 1586–1595, 2007. View at Publisher · View at Google Scholar · View at Scopus
  115. R. Fronczek, S. Overeem, S. Y. Y. Lee et al., “Hypocretin (orexin) loss in Parkinson's disease,” Brain, vol. 130, no. 6, pp. 1577–1585, 2007. View at Publisher · View at Google Scholar · View at Scopus
  116. Y. Compta, J. Santamaria, L. Ratti et al., “Cerebrospinal hypocretin, daytime sleepiness and sleep architecture in Parkinson's disease dementia,” Brain, vol. 132, no. 12, pp. 3308–3317, 2009. View at Publisher · View at Google Scholar · View at Scopus
  117. H. Asai, M. Hirano, Y. Furiya et al., “Cerebrospinal fluid-orexin levels and sleep attacks in four patients with Parkinson's disease,” Clinical Neurology and Neurosurgery, vol. 111, no. 4, pp. 341–344, 2009. View at Publisher · View at Google Scholar · View at Scopus
  118. J. Kulisevsky, J. Pagonbarraga, B. Pascual-Sedano, C. García-Sánchez, and A. Gironell, “Prevalence and correlates of neuropsychiatric symptoms in Parkinson's disease without dementia,” Movement Disorders, vol. 23, no. 13, pp. 1889–1896, 2008. View at Publisher · View at Google Scholar
  119. I. Ferrer, “Early involvement of the cerebral cortex in Parkinson's disease: convergence of multiple metabolic defects,” Progress in Neurobiology, vol. 88, no. 2, pp. 89–103, 2009. View at Publisher · View at Google Scholar · View at Scopus
  120. H. Braak, U. Rüb, E. N. H. Jansen Steur, K. Del Tredici, and R. A. I. De Vos, “Cognitive status correlates with neuropathologic stage in Parkinson disease,” Neurology, vol. 64, no. 8, pp. 1404–1410, 2005. View at Google Scholar · View at Scopus
  121. D. W. Dickson, H. Uchikado, H. Fujishiro, and Y. Tsuboi, “Evidence in favor of Braak staging of Parkinson's disease,” Movement Disorders, vol. 25, supplement 1, pp. S78–82, 2010. View at Publisher · View at Google Scholar · View at Scopus
  122. P. M. Mattila, J. O. Rinne, H. Helenius, D. W. Dickson, and M. Röyttä, “Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease,” Acta Neuropathologica, vol. 100, no. 3, pp. 285–290, 2000. View at Google Scholar
  123. J. Molano, B. Boeve, T. Ferman et al., “Mild cognitive impairment associated with limbic and neocortical Lewy body disease: a clinicopathological study,” Brain, vol. 133, no. 2, pp. 540–556, 2010. View at Publisher · View at Google Scholar · View at Scopus
  124. L. Parkkinen, T. Kauppinen, T. Pirttilä, J. M. Autere, and I. Alafuzoff, “α-synuclein pathology does not predict extrapyramidal symptoms or dementia,” Annals of Neurology, vol. 57, no. 1, pp. 82–91, 2005. View at Publisher · View at Google Scholar · View at Scopus
  125. L. Parkkinen, T. Pirttilä, M. Tervahauta, and I. Alafuzoff, “Widespread and abundant α-synuclein pathology in a neurologically unimpaired subject,” Neuropathology, vol. 25, no. 4, pp. 304–314, 2005. View at Publisher · View at Google Scholar · View at Scopus
  126. D. Weisman, M. Cho, C. Taylor, A. Adame, L. J. Thal, and L. A. Hansen, “In dementia with Lewy bodies, Braak stage determines phenotype, not Lewy body distribution,” Neurology, vol. 69, no. 4, pp. 356–359, 2007. View at Publisher · View at Google Scholar · View at Scopus
  127. L. Parkkinen, T. Pirttilâ, and I. Alafuzoff, “Applicability of current staging/categorization of α-synuclein pathology and their clinical relevance,” Acta Neuropathologica, vol. 115, no. 4, pp. 399–407, 2008. View at Publisher · View at Google Scholar · View at Scopus
  128. R. E. Burke, W. T. Dauer, and J. P. G. Vonsattel, “A critical evaluation of the Braak staging scheme for Parkinson's disease,” Annals of Neurology, vol. 64, no. 5, pp. 485–491, 2008. View at Publisher · View at Google Scholar · View at Scopus
  129. G. Halliday, M. Hely, W. Reid, and J. Morris, “The progression of pathology in longitudinally followed patients with Parkinson's disease,” Acta Neuropathologica, vol. 115, no. 4, pp. 409–415, 2008. View at Publisher · View at Google Scholar · View at Scopus
  130. A. J. Harding, G. A. Broe, and G. M. Halliday, “Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe,” Brain, vol. 125, no. 2, pp. 391–403, 2002. View at Google Scholar · View at Scopus
  131. R. Yamamoto, E. Iseki, N. Murayama et al., “Correlation in Lewy pathology between the claustrum and visual areas in brains of dementia with Lewy bodies,” Neuroscience Letters, vol. 415, no. 3, pp. 219–224, 2007. View at Publisher · View at Google Scholar
  132. M. E. Kalaitzakis, L. M. Christian, L. B. Moran, M. B. Graeber, R. K. B. Pearce, and S. M. Gentleman, “Dementia and visual hallucinations associated with limbic pathology in Parkinson's disease,” Parkinsonism and Related Disorders, vol. 15, no. 3, pp. 196–204, 2009. View at Publisher · View at Google Scholar · View at Scopus
  133. G. Muntané, E. Dalfó, A. Martinez, and I. Ferrer, “Phosphorylation of tau and α-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related α-synucleinopathies,” Neuroscience, vol. 152, no. 4, pp. 913–923, 2008. View at Publisher · View at Google Scholar
  134. W. J. Schulz-Schaeffer, “The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia,” Acta Neuropathologica, vol. 120, pp. 131–143, 2010. View at Publisher · View at Google Scholar · View at Scopus
  135. K. Tanji, F. Mori, J. Mimura et al., “Proteinase K-resistant α-synuclein is deposited in presynapses in human Lewy body disease and A53T α-synuclein transgenic mice,” Acta Neuropathologica, vol. 120, no. 2, pp. 145–154, 2010. View at Publisher · View at Google Scholar
  136. E. Dalfó, M. Barrachina, J. L. Rosa, S. Ambrosio, and I. Ferrer, “Abnormal α-synuclein interactions with rab3a and rabphilin in diffuse Lewy body disease,” Neurobiology of Disease, vol. 16, no. 1, pp. 92–97, 2004. View at Publisher · View at Google Scholar · View at Scopus
  137. E. Dalfó, J. L. Albasanz, M. Martín, and I. Ferrer, “Abnormal metabotropic glutamate receptor expression and signaling in the cerebral cortex in diffuse Lewy body disease is associated with irregular α-synuclein/phospholipase C (PLCβ1) interactions,” Brain Pathology, vol. 14, no. 4, pp. 388–398, 2004. View at Google Scholar
  138. A. M. Owen, J. Doyon, A. Dagher, A. Sadikot, and A. C. Evans, “Abnormal basal ganglia outflow in Parkinson's disease identified with PET. Implications for higher cortical functions,” Brain, vol. 121, no. 5, pp. 949–965, 1998. View at Publisher · View at Google Scholar · View at Scopus
  139. G. Dirnberger, C. D. Frith, and M. Jahanshahi, “Executive dysfunction in Parkinson's disease is associated with altered pallidal-frontal processing,” NeuroImage, vol. 25, no. 2, pp. 588–599, 2005. View at Publisher · View at Google Scholar · View at Scopus
  140. R. Cools, E. Stefanova, R. A. Barker, T. W. Robbins, and A. M. Owen, “Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET,” Brain, vol. 125, no. 3, pp. 584–594, 2002. View at Google Scholar · View at Scopus
  141. O. Monchi, M. Petrides, B. Mejia-Constain, and A. P. Strafella, “Cortical activity in Parkinson's disease during executive processing depends on striatal involvement,” Brain, vol. 130, no. 1, pp. 233–244, 2007. View at Publisher · View at Google Scholar · View at Scopus
  142. P. Marklund, A. Larsson, E. Elgh et al., “Temporal dynamics of basal ganglia under-recruitment in Parkinson's disease: transient caudate abnormalities during updating of working memory,” Brain, vol. 132, no. 2, pp. 336–346, 2009. View at Publisher · View at Google Scholar
  143. R. Y. Moore, A. L. Whone, and D. J. Brooks, “Extrastriatal monoamine neuron function in Parkinson's disease: an 18F-dopa PET study,” Neurobiology of Disease, vol. 29, no. 3, pp. 381–390, 2008. View at Publisher · View at Google Scholar
  144. V. L. Cropley, M. Fujita, W. Bara-Jimenez et al., “Pre- and post-synaptic dopamine imaging and its relation with frontostriatal cognitive function in Parkinson disease: PET studies with [11C]NNC 112 and [F]FDOPA,” Psychiatry Research, vol. 163, no. 2, pp. 171–182, 2008. View at Publisher · View at Google Scholar · View at Scopus
  145. N. Sawamoto, P. Piccini, G. Hotton, N. Pavese, K. Thielemans, and D. J. Brooks, “Cognitive deficits and striato-frontal dopamine release in Parkinson's disease,” Brain, vol. 131, no. 5, pp. 1294–1302, 2008. View at Publisher · View at Google Scholar · View at Scopus
  146. C. Zarow, S. A. Lyness, J. A. Mortimer, and H. C. Chui, “Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases,” Archives of Neurology, vol. 60, no. 3, pp. 337–341, 2003. View at Publisher · View at Google Scholar
  147. J. L. W. Bosboom, D. Stoffers, and E. CH. Wolters, “The role of acetylcholine and dopamine in dementia and psychosis in Parkinson's disease,” Journal of Neural Transmission, Supplement, no. 65, pp. 185–195, 2003. View at Google Scholar · View at Scopus
  148. R. Hilker, A. V. Thomas, J. C. Klein et al., “Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways,” Neurology, vol. 65, no. 11, pp. 1716–1722, 2005. View at Publisher · View at Google Scholar · View at Scopus
  149. S. J. Baloyannis, V. Costa, and I. S. Baloyannis, “Morphological alterations of the synapses in the locus coeruleus in Parkinson's disease,” Journal of the Neurological Sciences, vol. 248, no. 1-2, pp. 35–41, 2006. View at Publisher · View at Google Scholar · View at Scopus
  150. B. Dubois, B. Pillon, F. Lhermitte, and Y. Agid, “Cholinergic deficiency and frontal dysfunction in Parkinson's disease,” Annals of Neurology, vol. 28, no. 2, pp. 117–121, 1990. View at Publisher · View at Google Scholar · View at Scopus
  151. P. Calabresi, B. Picconi, L. Parnetti, and M. Di Filippo, “A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine-acetylcholine synaptic balance,” Lancet Neurology, vol. 5, no. 11, pp. 974–983, 2006. View at Publisher · View at Google Scholar · View at Scopus
  152. H. Shimada, S. Hirano, H. Shinotoh et al., “Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET,” Neurology, vol. 73, no. 4, pp. 273–278, 2009. View at Publisher · View at Google Scholar · View at Scopus
  153. N. I. Bohnen and R. L. Albin, “Cholinergic denervation occurs early in Parkinson disease,” Neurology, vol. 73, no. 4, pp. 256–257, 2009. View at Publisher · View at Google Scholar · View at Scopus
  154. N. I. Bohnen and R. L. Albin, “The cholinergic system and Parkinson disease,” Behavioural Brain Research. In press.
  155. F. Roselli, N. M. Pisciotta, M. Pennelli et al., “Midbrain SERT in degenerative parkinsonisms: a 123I-FP-CIT SPECT study,” Movement Disorders, vol. 25, no. 12, pp. 1853–1859, 2010. View at Publisher · View at Google Scholar
  156. S. W. Yong, J. K. Yoon, Y. S. An, and P. H. Lee, “A comparison of cerebral glucose metabolism in Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies,” European Journal of Neurology, vol. 14, no. 12, pp. 1357–1362, 2007. View at Publisher · View at Google Scholar · View at Scopus
  157. A. Wallin, S. Ekberg, K. Lind, V. Milos, A.-K. Granérus, and G. Granerus, “Posterior cortical brain dysfunction in cognitively impaired patients with Parkinson's disease—a rCBF scintigraphy study,” Acta Neurologica Scandinavica, vol. 116, no. 6, pp. 347–354, 2007. View at Publisher · View at Google Scholar
  158. C. Huang, C. Tang, A. Feigin et al., “Changes in network activity with the progression of Parkinson's disease,” Brain, vol. 130, no. 7, pp. 1834–1846, 2007. View at Publisher · View at Google Scholar · View at Scopus
  159. C. Huang, P. Mattis, K. Perrine, N. Brown, V. Dhawan, and D. Eidelberg, “Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease,” Neurology, vol. 70, no. 16, pp. 1470–1477, 2008. View at Publisher · View at Google Scholar · View at Scopus
  160. C. Tessa, M. Giannelli, R. Della Nave et al., “A whole-brain analysis in de novo Parkinson disease,” American Journal of Neuroradiology, vol. 29, no. 4, pp. 674–680, 2008. View at Publisher · View at Google Scholar
  161. A. T. Karagulle Kendi, S. Lehericy, M. Luciana, K. Ugurbil, and P. Tuite, “Altered diffusion in the frontal lobe in Parkinson disease,” American Journal of Neuroradiology, vol. 29, no. 3, pp. 501–505, 2008. View at Publisher · View at Google Scholar · View at Scopus
  162. S.-J. Lee, J.-S. Kim, J.-Y. Yoo et al., “Influence of white matter hyperintensities on the cognition of patients with parkinson disease,” Alzheimer Disease and Associated Disorders, vol. 24, no. 3, pp. 227–233, 2010. View at Publisher · View at Google Scholar
  163. K. A. Jellinger, “Prevalence and impact of cerebrovascular lesions in Alzheimer and Lewy body diseases,” Neurodegenerative Diseases, vol. 7, no. 1–3, pp. 112–115, 2010. View at Publisher · View at Google Scholar · View at Scopus
  164. A. H. Schapira, “Mitochondria in the aetiology and pathogenesis of Parkinson's disease,” The Lancet Neurology, vol. 7, no. 1, pp. 97–109, 2008. View at Publisher · View at Google Scholar · View at Scopus
  165. G. H. Sack, “Mitochondrial matters in Parkinson disease: introduction,” Journal of Bioenergetics and Biomembranes, vol. 41, no. 6, pp. 465–467, 2009. View at Publisher · View at Google Scholar · View at Scopus
  166. K. F. Winklhofer and C. Haass, “Mitochondrial dysfunction in Parkinson's disease,” Biochimica et Biophysica Acta, vol. 1802, no. 1, pp. 29–44, 2010. View at Publisher · View at Google Scholar · View at Scopus
  167. P. M. Abou-Sleiman, M. M. K. Muqit, and N. W. Wood, “Expanding insights of mitochondrial dysfunction in Parkinson's disease,” Nature Reviews Neuroscience, vol. 7, no. 3, pp. 207–219, 2006. View at Publisher · View at Google Scholar · View at Scopus
  168. Y. Yang, S. Gehrke, MD. E. Haque et al., “Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 38, pp. 13670–13675, 2005. View at Publisher · View at Google Scholar · View at Scopus
  169. R. Ved, S. Saha, B. Westlund et al., “Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of α-synuclein, parkin, and DJ-1 in Caenorhabditis elegans,” Journal of Biological Chemistry, vol. 280, no. 52, pp. 42655–42668, 2005. View at Publisher · View at Google Scholar
  170. L. Silvestri, V. Caputo, E. Bellacchio et al., “Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism,” Human Molecular Genetics, vol. 14, no. 22, pp. 3477–3492, 2005. View at Publisher · View at Google Scholar · View at Scopus
  171. J. Park, S. B. Lee, S. Lee et al., “Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin,” Nature, vol. 441, no. 7097, pp. 1157–1161, 2006. View at Publisher · View at Google Scholar · View at Scopus
  172. I. E. Clark, M. W. Dodson, C. Jiang et al., “Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin,” Nature, vol. 441, no. 7097, pp. 1162–1166, 2006. View at Publisher · View at Google Scholar · View at Scopus
  173. A. C. Poole, R. E. Thomas, L. A. Andrews, H. M. McBride, A. J. Whitworth, and L. J. Pallanck, “The PINK1/Parkin pathway regulates mitochondrial morphology,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 5, pp. 1638–1643, 2008. View at Publisher · View at Google Scholar
  174. W. W. Smith, Z. Pei, H. Jiang et al., “Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 51, pp. 18676–18681, 2005. View at Publisher · View at Google Scholar · View at Scopus
  175. Y. Suzuki, Y. Imai, H. Nakayama, K. Takahashi, K. Takio, and R. Takahashi, “A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death,” Molecular Cell, vol. 8, no. 3, pp. 613–621, 2001. View at Publisher · View at Google Scholar · View at Scopus
  176. M. W. Dodson and M. Guo, “Pink1, Parkin, DJ-1 and mitochondrial dysfunction in Parkinson's disease,” Current Opinion in Neurobiology, vol. 17, no. 3, pp. 331–337, 2007. View at Publisher · View at Google Scholar · View at Scopus
  177. R. K. Dagda and C. T. Chu, “Mitochondrial quality control: insights on how Parkinson's disease related genes PINK1, parkin, and Omi/HtrA2 interact to maintain mitochondrial homeostasis,” Journal of Bioenergetics and Biomembranes, vol. 41, no. 6, pp. 473–479, 2009. View at Publisher · View at Google Scholar · View at Scopus
  178. M. Jendrach, S. Gispert, F. Ricciardi, M. Klinkenberg, R. Schemm, and G. Auburger, “The mitochondrial kinase PINK1, stress response and Parkinson's disease,” Journal of Bioenergetics and Biomembranes, vol. 41, no. 6, pp. 481–486, 2009. View at Publisher · View at Google Scholar · View at Scopus
  179. A. J. Whitworth and L. J. Pallanck, “The PINK1/Parkin pathway: a mitochondrial quality control system?” Journal of Bioenergetics and Biomembranes, vol. 41, no. 6, pp. 499–503, 2009. View at Publisher · View at Google Scholar · View at Scopus
  180. S. Papa, A. M. Sardanelli, N. Capitanio, and C. Piccoli, “Mitochondrial respiratory dysfunction and mutations in mitochondrial DNA in PINK1 familial Parkinsonism,” Journal of Bioenergetics and Biomembranes, vol. 41, no. 6, pp. 509–516, 2009. View at Publisher · View at Google Scholar · View at Scopus
  181. A. Navarro, A. Boveris, M. J. Bández et al., “Human brain cortex: mitochondrial oxidative damage and adaptive response in Parkinson disease and in dementia with Lewy bodies,” Free Radical Biology and Medicine, vol. 46, no. 12, pp. 1574–1580, 2009. View at Publisher · View at Google Scholar · View at Scopus
  182. A. Navarro and A. Boveris, “Brain mitochondrial dysfunction and oxidative damage in Parkinson's disease,” Journal of Bioenergetics and Biomembranes, vol. 41, no. 6, pp. 517–521, 2009. View at Publisher · View at Google Scholar · View at Scopus
  183. P. M. Keeney, J. Xie, R. A. Capaldi, and J. P. Bennett, “Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled,” Journal of Neuroscience, vol. 26, no. 19, pp. 5256–5264, 2006. View at Publisher · View at Google Scholar · View at Scopus
  184. E. Hattingen, J. Magerkurth, U. Pilatus et al., “Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson's disease,” Brain, vol. 132, no. 12, pp. 3285–3297, 2009. View at Publisher · View at Google Scholar · View at Scopus
  185. Z. I. Alam, S. E. Daniel, A. J. Lees, D. C. Marsden, P. Jenner, and B. Halliwell, “A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease,” Journal of Neurochemistry, vol. 69, no. 3, pp. 1326–1329, 1997. View at Google Scholar · View at Scopus
  186. E. Dalfó, M. Portero-Otín, V. Ayala, A. Martínez, R. Pamplona, and I. Ferrer, “Evidence of oxidative stress in the neocortex in incidental Lewy body disease,” Journal of Neuropathology and Experimental Neurology, vol. 64, no. 9, pp. 816–830, 2005. View at Google Scholar · View at Scopus
  187. E. Dalfó and I. Ferrer, “Early α-synuclein lipoxidation in neocortex in Lewy body diseases,” Neurobiology of Aging, vol. 29, no. 3, pp. 408–417, 2008. View at Publisher · View at Google Scholar · View at Scopus
  188. J. Choi, A. I. Levey, S. T. Weintraub et al., “Oxidative Modifications and Down-regulation of Ubiquitin Carboxyl-terminal Hydrolase L1 Associated with Idiopathic Parkinson's and Alzheimer's Diseases,” Journal of Biological Chemistry, vol. 279, no. 13, pp. 13256–13264, 2004. View at Publisher · View at Google Scholar · View at Scopus
  189. J. Choi, H. D. Rees, S. T. Weintraub, A. I. Levey, L. S. Chin, and L. Li, “Oxidative modifications and aggregation of Cu,Zn-superoxide dismutase associated with alzheimer and Parkinson diseases,” Journal of Biological Chemistry, vol. 280, no. 12, pp. 11648–11655, 2005. View at Publisher · View at Google Scholar · View at Scopus
  190. J. Choi, M. C. Sullards, J. A. Olzmann et al., “Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases,” Journal of Biological Chemistry, vol. 281, no. 16, pp. 10816–10824, 2006. View at Publisher · View at Google Scholar · View at Scopus
  191. A. Gómez and I. Ferrer, “Increased oxidation of certain glycolysis and energy metabolism enzymes in the frontal cortex in Lewy body diseases,” Journal of Neuroscience Research, vol. 87, no. 4, pp. 1002–1013, 2009. View at Publisher · View at Google Scholar · View at Scopus
  192. J. H. T. Power and P. C. Blumbergs, “Cellular glutathione peroxidase in human brain: cellular distribution, and its potential role in the degradation of Lewy bodies in Parkinson's disease and dementia with Lewy bodies,” Acta Neuropathologica, vol. 117, no. 1, pp. 63–73, 2009. View at Publisher · View at Google Scholar · View at Scopus
  193. C. C. Tang, K. L. Poston, V. Dhawan, and D. Eidelberg, “Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease,” Journal of Neuroscience, vol. 30, no. 3, pp. 1049–1056, 2010. View at Publisher · View at Google Scholar · View at Scopus
  194. N. Fabelo, V. Martín, G. Santpere et al., “Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson’s disease and incidental Parkinson’s disease,” submitted.
  195. I. Ferrer, “Altered mitochondria, energy metabolism, voltage-dependent anion channel, and lipid rafts converge to exhaust neurons in Alzheimer's disease,” Journal of Bioenergetics and Biomembranes, vol. 41, no. 5, pp. 425–431, 2009. View at Publisher · View at Google Scholar · View at Scopus
  196. A. Gomez and I. Ferrer, “Involvement of the cerebral cortex in Parkinson disease linked with G2019S LRRK2 mutation without cognitive impairment,” Acta Neuropathologica, vol. 20, pp. 155–167, 2010. View at Publisher · View at Google Scholar · View at Scopus
  197. A. McKinlay, R. C. Grace, J. C. Dalrymple-Alford, and D. Roger, “Cognitive characteristics associated with mild cognitive impairment in parkinson's disease,” Dementia and Geriatric Cognitive Disorders, vol. 28, no. 2, pp. 121–129, 2009. View at Publisher · View at Google Scholar · View at Scopus
  198. K. F. Pedersen, G. Alves, D. Aarsland, and J. P. Larsen, “Occurrence and risk factors for apathy in Parkinson disease: a 4-year prospective longitudinal study,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 80, no. 11, pp. 1279–1282, 2009. View at Publisher · View at Google Scholar · View at Scopus
  199. J. R. Sanchez-Ramos, R. Ortoll, and G. W. Paulson, “Visual hallucinations associated with Parkinson disease,” Archives of Neurology, vol. 53, no. 12, pp. 1265–1268, 1996. View at Google Scholar · View at Scopus
  200. R. Inzelberg, S. Kipervasser, and A. D. Korczyn, “Auditory hallucinations in Parkinson's disease,” Journal of Neurology Neurosurgery and Psychiatry, vol. 64, no. 4, pp. 533–535, 1998. View at Google Scholar · View at Scopus
  201. E. CH. Wolters, “Intrinsic and extrinsic psychosis in Parkinson's disease,” Journal of Neurology, Supplement, vol. 248, supplement 3, pp. III22–III27, 2001. View at Google Scholar · View at Scopus
  202. A. D. de Maindreville, G. Fénelon, and F. Mahieux, “Hallucinations in Parkinson's disease: a follow-up study,” Movement Disorders, vol. 20, no. 2, pp. 212–217, 2005. View at Publisher · View at Google Scholar · View at Scopus
  203. S. Papapetropoulos and D. C. Mash, “Psychotic symptoms in Parkinson's disease: from description to etiology,” Journal of Neurology, vol. 252, no. 7, pp. 753–764, 2005. View at Publisher · View at Google Scholar · View at Scopus
  204. W. Birkmayer and P. Riederer, “Responsibility of extrastriatal areas for the appearance of psychotic symptoms. (Clinical and biochemical human post mortem findings),” Journal of Neural Transmission, vol. 37, no. 2, pp. 175–182, 1975. View at Google Scholar · View at Scopus
  205. R. Mayeux, Y. Stern, and J. B.W. Williams, “Clinical and biochemical features of depression in Parkinson's disease,” American Journal of Psychiatry, vol. 143, no. 6, pp. 756–759, 1986. View at Google Scholar
  206. E. K. Perry, I. McKeith, P. Thompson et al., “Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson's disease, and Alzheimer's disease,” Annals of the New York Academy of Sciences, vol. 640, pp. 197–202, 1991. View at Google Scholar · View at Scopus
  207. P. Remy, M. Doder, A. Lees, N. Turjanski, and D. Brooks, “Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system,” Brain, vol. 128, no. 6, pp. 1314–1322, 2005. View at Publisher · View at Google Scholar · View at Scopus
  208. P. G. Frisina, V. Haroutunian, and L. S. Libow, “The neuropathological basis for depression in Parkinson's disease,” Parkinsonism and Related Disorders, vol. 15, no. 2, pp. 144–148, 2009. View at Publisher · View at Google Scholar · View at Scopus
  209. J. A. Parkinson, T. W. Robbins, and B. J. Everitt, “Dissociable roles of the central and basolateral amygdala in appetitive emotional learning,” European Journal of Neuroscience, vol. 12, no. 1, pp. 405–413, 2000. View at Publisher · View at Google Scholar · View at Scopus
  210. B. J. Everitt, R. N. Cardinal, J. A. Parkinson, and T. W. Robbins, “Appetitive behavior: impact of amygdala-dependent mechanisms of emotional learning,” Annals of the New York Academy of Sciences, vol. 985, pp. 233–250, 2003. View at Google Scholar · View at Scopus
  211. Y. Kan, M. Kawamura, Y. Hasegawa, S. Mochizuki, and K. Nakamura, “Recognition of emotion from facial, prosodic and written verbal stimuli in Parkinson's disease,” Cortex, vol. 38, no. 4, pp. 623–630, 2002. View at Google Scholar · View at Scopus
  212. N. Yoshimura, M. Kawamura, Y. Masaoka, and I. Homma, “The amygdala of patients with Parkinson's disease is silent in response to fearful facial expressions,” Neuroscience, vol. 131, no. 2, pp. 523–534, 2005. View at Publisher · View at Google Scholar · View at Scopus
  213. N. Ibarretxe-Bilbao, C. Junque, E. Tolosa et al., “Neuroanatomical correlates of impaired decision-making and facial emotion recognition in early Parkinson's disease,” European Journal of Neuroscience, vol. 30, no. 6, pp. 1162–1171, 2009. View at Publisher · View at Google Scholar · View at Scopus
  214. P. Delaveau, P. Salgado-Pineda, T. Witjas et al., “Dopaminergic modulation of amygdala activity during emotion recognition in patients with parkinson disease,” Journal of Clinical Psychopharmacology, vol. 29, no. 6, pp. 548–554, 2009. View at Publisher · View at Google Scholar · View at Scopus